Catharina C Gross, Andreas Schulte-Mecklenbeck, Olga V Steinberg, Timo Wirth, Sarah Lauks, Stefan Bittner, Patrick Schindler, Sergio E Baranzini, Sergiu Groppa, Judith Bellmann-Strobl, Nora Bünger, Claudia Chien, Eva Dawin, Maria Eveslage, Vinzenz Fleischer, Gabriel Gonzalez-Escamilla, Barbara Gisevius, Jürgen Haas, Martin Kerschensteiner, Lucienne Kirstein, Catharina Korsukewitz, Lisa Lohmann, Jan D Lünemann, Felix Luessi, Gerd Meyer Zu Hörste, Jeremias Motte, Tobias Ruck, Klemens Ruprecht, Nicholas Schwab, Falk Steffen, Sven G Meuth, Friedemann Paul, Brigitte Wildemann, Tania Kümpfel, Ralf Gold, Tim Hahn, Frauke Zipp, Luisa Klotz, Heinz Wiendl
One of the biggest challenges in managing multiple sclerosis is the heterogeneity of clinical manifestations and progression trajectories. It still remains to be elucidated whether this heterogeneity is reflected by discrete immune signatures in the blood as a surrogate of disease pathophysiology. Accordingly, individualized treatment selection based on immunobiological principles is still not feasible. Using two independent multicentric longitudinal cohorts of patients with early multiple sclerosis ( n = 309 discovery and n = 232 validation), we were able to identify three distinct peripheral blood immunological endophenotypes by a combination of high-dimensional flow cytometry and serum proteomics, followed by unsupervised clustering...
March 27, 2024: Science Translational Medicine